Edition:
United States

Alkermes Plc (ALKS.O)

ALKS.O on Nasdaq

53.99USD
1:34pm EST
Change (% chg)

$1.01 (+1.91%)
Prev Close
$52.98
Open
$53.06
Day's High
$54.04
Day's Low
$52.54
Volume
637,016
Avg. Vol
1,095,573
52-wk High
$60.74
52-wk Low
$27.14

Select another date:

Wed, Feb 15 2017

BRIEF-Alkermes Q4 non-gaap earnings per share $0.15

* Alkermes plc reports financial results for the year ended dec. 31, 2016 and provides financial expectations for 2017

BRIEF-Alkermes inspiration grants awarded to support people affected by mental health and substance use disorders

* Alkermes inspiration grants(tm) awarded to support people affected by mental health and substance use disorders Source text for Eikon: Further company coverage:

BRIEF-Alkermes Q3 loss per share $0.41

* Alkermes plc qtrly royalty revenue from Bydureon was $11.6 million, compared to $13.0 million for same period in prior year

U.S. RESEARCH ROUNDUP-Alkermes, Chesapeake Energy Corp, Latam Airlines

Oct 21 Wall Street securities analysts revised their ratings and price targets on several U.S.-listed companies, including Alkermes, Benchmark Electronics and Copa Holdings on Friday. HIGHLIGHTS * Chesapeake Energy Corp : Nomura raises to neutral from reduce * Latam Airlines : Santander raises to buy from hold * Proofpoint Inc : Piper Jaffray raises target price to $90 from $85; overweight Following is a sum

Alkermes depression drug succeeds in key trial; shares surge

Alkermes Plc's experimental depression drug significantly reduced symptoms in patients suffering from major depressive disorder who were not helped by standard treatments in a pivotal late-stage trial, the company said on Thursday, and its shares surged 47 percent.

UPDATE 2-Alkermes depression drug succeeds in key trial; shares surge

Oct 20 Alkermes Plc's experimental depression drug significantly reduced symptoms in patients suffering from major depressive disorder who were not helped by standard treatments in a pivotal late-stage trial, the company said on Thursday, and its shares surged 47 percent.

Alkermes depression drug meets main goal; shares surge

Oct 20 Alkermes Plc said its lead depression drug met the main goal of a late-stage trial, sending its shares up 48 pct in extended trading.

BRIEF-Alkermes announces topline results from phase 3 study of Alks 5461

* Alkermes announces positive topline results from forward-5 pivotal phase 3 study of alks 5461 for major depressive disorder

BRIEF-Alkermes, certain subsidiaries enter into amendment to amended, restated credit agreement

* Alkermes - On Oct. 12, co, certain other subsidiaries of company entered into an amendment to amended and restated credit agreement - SEC filing

Select another date:

More From Around the Web